Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
127.85
-3.87 (-2.94%)
Sep 4, 2025, 3:43 PM - Market open
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
The 14 analysts that cover Jazz Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $178.93, which forecasts a 39.95% increase in the stock price over the next year. The lowest target is $147 and the highest is $217.
Price Target: $178.93 (+39.95%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Jazz Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 5 | 5 |
| Buy | 7 | 7 | 7 | 7 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 12 | 12 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $162 → $185 | Strong Buy | Maintains | $162 → $185 | +44.70% | Aug 29, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $162 → $163 | Buy | Maintains | $162 → $163 | +27.49% | Aug 28, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $145 → $151 | Buy | Maintains | $145 → $151 | +18.11% | Aug 28, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $200 → $205 | Strong Buy | Maintains | $200 → $205 | +60.34% | Aug 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $202 | Strong Buy | Reiterates | $202 | +58.00% | Aug 28, 2025 |
Financial Forecast
Revenue This Year
4.30B
from 4.07B
Increased by 5.65%
Revenue Next Year
4.55B
from 4.30B
Increased by 5.79%
EPS This Year
5.35
from 8.65
Decreased by -38.14%
EPS Next Year
22.01
from 5.35
Increased by 311.41%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.5B | 5.0B | |||
| Avg | 4.3B | 4.5B | |||
| Low | 4.1B | 4.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.9% | 16.8% | |||
| Avg | 5.7% | 5.8% | |||
| Low | 0.2% | -5.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.88 | 26.72 | |||
| Avg | 5.35 | 22.01 | |||
| Low | 4.77 | 16.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -32.0% | 399.5% | |||
| Avg | -38.1% | 311.4% | |||
| Low | -44.8% | 206.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.